Substance / Medication

Ombitasvir

SNOMED 713479007 UMLS C3852670

Overview

Active Ingredient

ombitasvir

RxNorm CUI

1597371

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Viral hepatitis C

Chronic type C viral hepatitis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

NCT02460133Phase 4Active Not Recruiting44 enrolled

Study of Oral Treatments for Hepatitis C

NCT02786537Phase 4Completed1275 enrolled

Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

NCT02461745Phase 4Completed200 enrolled

Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

NCT03499639Phase 4Completed110 enrolled

Pilot HCV Direct Acting Antiviral Therapy and Metabolism

NCT02734173Phase 4Completed24 enrolled

View all 5 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.

Wedemeyer H, Craxí A, Zuckerman E et al. · J Viral Hepat · 2017

PMID: 28480525Meta-Analysis

Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.

Polepally Akshanth R, Badri Prajakta S, Eckert Doerthe et al. · Eur J Drug Metab Pharmacokinet · 2017

PMID: 27165046Meta-Analysis

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.

Ahmed Hussien, Abushouk Abdelrahman Ibrahim, Menshawy Amr et al. · Clin Drug Investig · 2017

PMID: 28871475Meta-Analysis

Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.

Schnell G, Tripathi R, Beyer J et al. · J Viral Hepat · 2018

PMID: 29624809RCT

Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.

Saab Sammy, Mehta Darshan, Hudgens Stacie et al. · Liver Int · 2018

PMID: 29314597RCT

[Efficacy and safety of paritaprevir/ritonavir/ombitasvir combined with dasabuvir in non-cirrhotic Asian adult patients with newly diagnosed and treated chronic HCV genotype 1b infection: a randomized, double-blind, placebo-controlled study - China data].

Wei L, Cheng J, Luo J et al. · Zhonghua Gan Zang Bing Za Zhi · 2018

PMID: 29996204RCT

TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.

Wyles David, Saag Michael, Viani Rolando M et al. · J Infect Dis · 2017

PMID: 28329334RCT

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.

Bacinschi Xenia, Popescu Gabriel Cristian, Zgura Anca et al. · Med Sci Monit · 2022

PMID: 35787600ObservationalFull text (PMC)

Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Değertekin Bülent, Demir Mehmet, Akarca Ulus S et al. · Turk J Gastroenterol · 2020

PMID: 33626001ObservationalFull text (PMC)

Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.

Abd-Elsalam Sherief, Abo-Amer Yousry Esam-Eldin, El-Abgeegy Mohamed et al. · Medicine (Baltimore) · 2020

PMID: 33080669ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ombitasvir (substance)
SNOMED CT: 713479007
UMLS CUI: C3852670
RxNorm CUI: 1597371

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.